[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Caroline Michaela Kistorp\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100575756","the-role-of-cardiac-inflammation-endothelial-dysfunction-and-fibrosis-in-fabry-disease-100575756",false,"NCT06776419","the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease","RATIFY","Patients with Fabry disease (1)\n\nInclusion Criteria:\n\n* Male and female individuals with a genetically-verified diagnosis of Fabry disease\n* ≥ 18 years of age\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Any contraindication against a pharmacologically induced rest-stress PET\u002FCT protocol according to local safety procedures such as acute coronary syndrome, severe bronchospasm, severe chronic obstructive pulmonary disease, cardiac arrhythmia.\n* Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup\u002Ftattoos that cannot be declared MR compatible.\n* Pregnancy\n\nAge and sex-matched healthy controls (2)\n\nInclusion Criteria:\n\n* ≥ 18 years of age\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A genetically-verified diagnosis of Fabry disease.\n* Family member to a patient with a genetically-verified diagnosis of Fabry disease\n* Cancer expected to influence life expectancy.\n* Known heart failure, previous apoplexy or previously established kidney disease.\n* Initiation or change of antihypertensive therapy within 3 months of enrollment.\n* Known LVH as evaluated on echocardiography\n* Any contraindication for a pharmacologically induced stress PET\u002FCT protocol according to local safety procedures such as acute coronary syndrome, severe bronchospasm, severe chronic obstructive pulmonary disease, cardiac arrhythmia.\n* Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup\u002Ftattoos that cannot be declared MR compatible.\n* Pregnancy",true,"ALL","18 Years",{"count":20,"type":21},54,"ESTIMATED","OBSERVATIONAL","The overall objective of this study is to investigate Fabry-related cardiomyopathy and the use of native T1-mapping, coronary microvascular function, cardiac inflammation, and cardiac injury in an effort to improve the ability to detect disease. The study aims to achieve this by:\n\n1. Investigating the association between cardiac inflammation, fibrosis, and injury against the distribution and degree of microvascular disease in patients with Fabry disease with and without left ventricular hypertrophy (LVH) using cardiac magnetic resonance (CMR) imaging and 82Rubidium Positron emission tomography and computer tomography (82Rb-PET\u002FCT).\n2. Using an extensive, in-depth biomarker blood panel to investigate the pathological pathways associated with Fabry disease and Fabry-related cardiomyopathy.",[25,26],"Fabry Disease","Cardiovascular Diseases",[28,29,30,31,32],"Hypertrophy","Inflammation; Myocardium","Fibrosis Myocardial","Endothelial dysfunction","Coronary Microcirculation","RECRUITING","2025-04-04",{"date":36,"type":37},"2025-04-08","ACTUAL",{"date":39,"type":21},"2025-05-01",{"date":41,"type":21},"2031-06-01",{"name":43,"class":44},"Caroline Michaela Kistorp","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100541102","fibrosis-inflammation-oxygenation-of-renal-tissue-in-fabry-disease-100541102","NCT06325488","Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease","FORTIFY","Fabry patients:\n\nInclusion Criteria:\n\n* Male and female individuals (≥18 years of age)\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Any contraindication for magnetic resonance imaging according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup\u002Ftattoos that cannot be declared MR compatible.\n* Pregnancy\n\nControl group Inclusion criteria\n\n* Male and female individuals (≥18 years of age)\n* Able to give informed consent Exclusion criteria\n* A genetically-verified diagnosis of Fabry disease.\n* Family member to a patient with a genetically-verified diagnosis of Fabry disease\n* Cancer expected to influence life expectancy.\n* Known heart failure, previous apoplexia or previously established kidney disease.\n* Initiation or change of antihypertensive therapy within 3 months of enrolment\n* Renal impairment as depicted by the CKD-EPI classification (≥ CKD G2\u002FA1)\n* Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup\u002Ftattoos that cannot be declared MR compatible.\n* Pregnancy",{"count":54,"type":21},60,"The overall objective of this study is to investigate Fabry-associated renal organ involvement by using a novel magnetic resonance imaging (MRI) approach, focusing on changes in renal oxygen levels by blood oxygenation-level dependent (BOLD) imaging. Furthermore, to correlate renal oxygenation to the phenotypic presentation of patients with Fabry-associated nephropathy regarding circulating and imaging-derived biomarkers of kidney inflammation, fibrosis and injury as compared with healthy age- and sex-matched controls.\n\nThe study will achieve this by:\n\n1\\) Using a non-invasive, contrast-free MRI protocol focusing on parameters of oxygenation, inflammation, fibrosis, and injury in the kidney.\n\n2\\) Using an extensive, in-depth biomarker blood panel to investigate the pathological pathways associated with Fabry disease and Fabry-associated nephropathy.",[25,57],"Chronic Kidney Diseases",[59,60,61],"Oxygenation","Inflammation","Fibrosis",{"date":63,"type":37},"2025-04-06",{"date":65,"type":37},"2024-06-01",{"date":67,"type":21},"2026-06-01",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100485312","prospective-longitudinal-study-on-fitness-doping-in-denmark-100485312","NCT05599438","Prospective, Longitudinal Study on FItness DOping in DenmarK","Prospective, Longitudinal Study of 800 Recreational Athletes With Current and Former Use of Performance and Image Enhancing Drugs (PIED), Focusing on Androgenic Anabolic Steroids (AAS) - Rigshospitalet","FIDO-DK\u002FRH","Inclusion Criteria:\n\n\\- Male and female recreational athletes (≥18 years of age) with current or former illicit use (\\>3 months since AAS cessation) of PIEDs (e.g. AAS) for a minimum four weeks\n\nInclusion Criteria (Controls, n = 100):\n\n\\- Male (n=80) or female (n=20) recreational athletes (≥18 years of age) with NO current or former illicit use of AAS.\n\nExclusion Criteria:\n\n* Severe psychiatric or somatic diseases which makes it impossible to give informed consent or comply with the investigatory program.\n* Known pregnancy.",{"count":78,"type":21},900,"15 Years","The aim of this prospective longitudinal study is to investigate the risks associated with use of anabolic steroids in fitness circles in Denmark in order to assess the scope of therapeutic need existing as a consequence of use. The objectives are:\n\n* To assess long-term complications and outcomes related to: cardiovascular disease, diabetes, gonadal disease (women and men) and psychiatric disease using data from Danish registries including addressing central questions such as whether the following characteristics play a role for development of overt disease\n* Characterization of illicit AAS use among men and women\n* Current male reproductive health\n* Current psychological well-being, aggressive tendencies, cognitive function and quality of life\n* Current cardiovascular and metabolic status\n\nThe participants will undergo:\n\n* Semi-structured medical interview\n* Physical examinations\n* Questionnaires\n* Blood and urine sampling\n* Dual X-ray Absorptiometry\n\nWith a subset undergoing further testing, including semen analysis, gonadotropin-releasing hormone (GnRH) and human chorionic gonadotropinm (hCG) stimulation and 82Rubidium positron emission tomography and computer tomography (PET\u002FCT).\n\nRegister-based follow-up is planned every third year until the 15th year, marking the completion of the trial.\n\nThe study will include 800 participants with current or former AAS use and 100 participants (80 male; 20 female) as controls with no former or current use of AAS.",[82,83,84,85,86,87],"Anabolic Steroid Overdose","Infertility","Cardiovascular Complication","Illicit Drug Use","Fitness","Mental Health Issue",[89,90,83,91],"Cardiovascular Disease","Metabolic syndrome","Mortality","2024-02-14",{"date":94,"type":37},"2024-02-15",{"date":96,"type":37},"2022-06-14",{"date":98,"type":21},"2040-06-01",{"name":43,"class":44},""]